Is ketamine therapy an effective treatment for alcohol use disorder? A new phase 2 study says YES!
The University of Exeter, in partnership with Awakn Life Sciences (OTCQB: AWKNF, NEO: AWKN) recently published data from their Ketamine psychotherapy to treat Alcohol Use Disorder (AUD), and the results were amazing. In this psychedelic-assisted therapy trial, 86% of individuals with Alcohol Use Disorder were found to be abstinent from the substance 6 months after treatment ended.
While up until this point there has been some evidence that ketamine and other psychedelics could effectively treat different forms of depression, this was the first evidence that the substance could also be used for addictions.
This is important, as 20% of adults suffer from one addiction or another, including 5% who suffer from alcoholism. Currently, there is no real treatment for any of these addictions, which tears a hole in society. If Awakn, and other ketamine and psychedelic companies, can come forward with a new and effective treatment, then this could be a paradigm shift for tens of millions of people.
Using psychedelics to improve mental health is a hot topic these days, but in order for psychedelic medicines to disrupt the traditional pharmaceutical industry when it comes to treating mental health conditions, we need to see solid evidence that they are effective. Trials like this one are a step in the right direction.
#Ketamine #Awakn #Psychedelics
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.